Renal cell carcinoma metastatic
Drug research and approvals for renal cell carcinoma metastatic: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 136 studies of renal cell carcinoma metastatic are recruiting on ClinicalTrials.gov, and Health Canada has authorized 15 drug trials for it since 2013.
- Recruiting worldwide: 136
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 0
- Histotripsy for Renal Cell CarcinomaNCT07943143 · Not applicable · The University of Hong Kong · starts Oct 13, 2026
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.NCT07937553 · Phase 2 · Kidney Cancer Research Bureau · starts Aug 15, 2025
- Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer PatientsNCT07928167 · Phase 2 · Kidney Cancer Research Bureau · starts Aug 25, 2025
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug…NCT07863024 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)NCT07782164 · Not reported · Amsterdam UMC, location VUmc · starts Apr 18, 2025
- Identification and Description of Patients With High-risk Non Metastatic RCCNCT07753343 · Not reported · University Hospital, Bordeaux · starts Apr 17, 2026
- Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell CarcinomaNCT07748988 · Phase 1 · Vanderbilt-Ingram Cancer Center · starts Sep 21, 2026
- Imaging Study in Metastatic Clear Cell RCC.NCT07671417 · Early Phase 1 · RayzeBio, Inc. · starts Jun 15, 2026
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic…NCT07667335 · Phase 1 / Phase 2 · Fred Hutchinson Cancer Center · starts Oct 20, 2026
How its trials ended
1,781 ClinicalTrials.gov studies of renal cell carcinoma in general, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 527 whose ending is known, 28% met their primary endpoint, 11% missed it and 61% stopped early.
- Completed, result not reported62235%
- Ongoing46926%
- Status unknown1639%
- Stopped: other or unclear1478%
- Met its primary endpoint1468%
- Stopped: enrollment or feasibility865%
- Missed its primary endpoint573%
- Stopped: sponsor or business decision432%
- Stopped: lack of efficacy282%
- Stopped: funding141%
- Stopped: safety6<1%
| Dec 21, 2020 | A phase 2, single-arm, open-label clinical trial of pembrolizumab plus lenvatinib in participants with first line advanced/metastatic non-clear cell renal cell…Pembrolizumab/ Lenvatinib | Merck & Co. (MSD) | Ongoing |
| Dec 14, 2017 | A randomized, open-label, phase 3 study to evaluate efficacy and safety of pembrolizumab (MK-3475) plus epacadostat vs standard of care (sunitinib or…Pembrolizumab (MK-3475) / Epacadostat (INCB024360) | Incyte | Closed |
| Aug 8, 2016 | A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy…Keytruda / Axitinib | Merck & Co. (MSD) | Ongoing |
| Jul 27, 2016 | A randomized, phase II efficacy assessment of multiple met kinase inhibitors (cabozantinib [nsc #761968], crizotinib [nsc #749005], savolitinib [nsc #785348],…Cabozantinib/ Crizotinib/ Savolitinib/ Sunitinib | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Closed |
| Apr 13, 2016 | A phase 2, open-label study to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128+MLN1117 compared with everolimus in the…Serabelisib (MLN1117)/ Sapanisertib (MLN0128)/ Everolimus | Takeda Pharmaceuticals USA | Closed |
| Mar 9, 2016 | A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with…Ciforadenant (CPI-444) / Atezolizumab | Corvus Pharmaceuticals | Closed |
| Feb 12, 2016 | A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride (AV-951) to sorafenib in subjects with refractory advanced…Tivozanib (AV-951) | LG Chem | Closed |
| Feb 4, 2016 | A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (INLYTA) versus sunitinib (SUTENT)…MSB0010718C (avelumab) / Axitinib / Sunitinib | Pfizer | Ongoing |
| Nov 27, 2015 | A multi-center, open label, randomized phase 2 study of AGS-16C3F vs axitinib in metastatic renal cell carcinomaAGS-16C3F / Axitinib | Astellas Pharma | Ongoing |
| Apr 9, 2015 | A phase III, open-label, randomized study of MPDL3280A (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated…RO5541267 (MPDL3280A, atezolizumab) / Bevacizumab / Fludeoxyglucose 18F /… | Roche | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA